Praxis Precision Medicines price to book ratio PRAX

Market value divided by the book value of the company's net assets, since 2021.

Today, Oct 23, 2026: 5.3×
6-year median: 2.6×
Against its 6-year history: 79th; percentile: 0 is its lowest day, 100 its highest
6-year range: 0.4× to 23.3×
Peer median: 10.6×

Praxis Precision Medicines' price to book ratio is 5.3× as of Oct 23, 2026.

That is above its 6-year median of 2.6×, higher than on 79% of days in the last 6 years.

Over that time it ranged from 0.4× in Jun 2022 to 23.3× in Feb 2026.

The median for 10 large drugmakers of a similar size is 10.6×.

Price to book ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	5.3×	5.0×	23.3×
2025	19.6×	1.3×	19.9×
2024	3.8×	2.1×	11.6×
2023	2.2×	0.6×	2.7×
2022	1.1×	0.4×	2.7×
2021	3.0×	2.0×	4.6×

Against its peers

Companies in Drug Manufacturers - General nearest Praxis Precision Medicines' size, closest first, today.

Company	Price to book ratio
PRAXPraxis Precision Medicines	5.3×
ALKSAlkermes plc.	4.0×
AMRXAmneal Pharmaceuticals	197×
LGNDLigand Pharmaceuticals	6.3×
TGTXTG Therapeutics	13.7×
KNSAKiniksa Pharmaceuticals International	9.2×
PTGXProtagonist Therapeutics	10.6×
CORTCorcept Therapeutics	13.2×
BMRNBiomarin Pharmaceutical	1.7×
INDVIndivior Pharmaceuticals	n/m
ARQTArcutis Biotherapeutics	17.8×
Peer median	10.6×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on Praxis Precision Medicines

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.